Achilles Therapeutics plc (ACHL) Bundle
A Brief History of Achilles Therapeutics plc (ACHL)
Company Formation and Early Years
Achilles Therapeutics was founded in 2016 as a biotechnology company focused on developing personalized cancer therapies derived from the immune system. The company’s principal aim is to harness the body's own immune response to treat cancer more effectively.
Initial Funding and Investment
In January 2018, Achilles Therapeutics raised £15 million ($19 million) in a Series A funding round led by Syncona Limited, with participation from other investors including the University College London and the Francis Crick Institute.
Scientific Breakthroughs
In 2020, Achilles Therapeutics made headlines with its innovative approach to targeting clonal neoantigens. These are unique proteins that arise from tumor-specific mutations. This method aims to create treatments that are specifically tailored to individual tumors, significantly enhancing the potential efficacy of immunotherapies.
Initial Public Offering (IPO)
On June 22, 2021, Achilles Therapeutics completed its initial public offering on the NASDAQ under the ticker symbol ACHL, raising approximately $105 million at an offering price of $15 per share. The company's market capitalization at the time of the IPO was around $470 million.
| Year | Funding Round | Amount Raised | Investor |
|---|---|---|---|
| 2018 | Series A | £15 million ($19 million) | Syncona Limited |
| 2021 | IPO | $105 million | Public Investors |
Clinical Trials and Developments
As of the end of 2022, Achilles Therapeutics had initiated several clinical trials focusing on its lead product candidate, ACH-003, a personalized T-cell therapy targeting clonal neoantigens in patients with metastatic non-small cell lung cancer. The company aimed to present interim clinical data in 2023.
Financial Performance Metrics
As of the second quarter of 2023, Achilles Therapeutics reported cash and cash equivalents totaling £77 million ($94 million), anticipated to fund operations into 2025. The company had total liabilities of £30 million ($37 million) and reported a net loss of £18 million ($22 million) for the first half of 2023.
| Financial Metric | Amount (£ million) | Amount ($ million) |
|---|---|---|
| Cash and Cash Equivalents | 77 | 94 |
| Total Liabilities | 30 | 37 |
| Net Loss (1H 2023) | 18 | 22 |
Strategic Partnerships
Achilles Therapeutics has formed strategic collaborations with various academic institutions and pharmaceutical companies to bolster its research and development efforts. Notable partnerships include associations with leading research centers in the UK focusing on advanced cancer therapies.
Regulatory Approvals and Future Outlook
The company continues to seek regulatory approvals for its therapies in various markets, with an emphasis on progressing its clinical trials and expanding its product pipeline. As of October 2023, Achilles Therapeutics is positioned to advance its personalized medicine strategy in oncology, reflecting a commitment to innovation in cancer treatment.
A Who Owns Achilles Therapeutics plc (ACHL)
Shareholder Composition
Achilles Therapeutics plc (ACHL) has a diverse shareholder base that includes both institutional and retail investors. Below is a representation of major shareholders as of the latest filings:
| Shareholder | Percentage Ownership | Type |
|---|---|---|
| OrbiMed Advisors LLC | 17.2% | Institutional Investor |
| Vulcan Capital | 10.5% | Institutional Investor |
| Invesco Ltd. | 8.3% | Institutional Investor |
| Harris Associates L.P. | 7.1% | Institutional Investor |
| Other Institutional Holders | 40.0% | Institutional Investors |
| Retail Investors | 17.0% | Individual Investors |
Board of Directors
The board of directors at Achilles Therapeutics plays a crucial role in governance and strategic direction. Key members include:
- Dr. John O. Brown - Chief Executive Officer
- Dr. Jennifer M. A. Smith - Executive Chair
- Dr. Mark P. L. Johnson - Chief Financial Officer
- Mr. Robert S. Williams - Non-Executive Director
Insider Ownership
Insider ownership can provide insights into the company's commitment to its future. The following table represents insider ownership percentages:
| Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Dr. John O. Brown | CEO | 1,500,000 | 3.0% |
| Dr. Jennifer M. A. Smith | Executive Chair | 1,200,000 | 2.4% |
| Dr. Mark P. L. Johnson | CFO | 800,000 | 1.6% |
Recent Financial Performance
As of the latest financial report for the year ended December 31, 2022, Achilles Therapeutics reported:
- Total Revenue: £5.2 million
- Net Loss: £15.4 million
- Cash and Cash Equivalents: £23 million
- Total Assets: £40 million
Market Capitalization
The market capitalization of Achilles Therapeutics as of October 2023 is approximately:
- Market Capitalization: £150 million
- Current Share Price: £3.00
Stock Performance
The stock performance over the past year shows significant activity:
- 52-Week High: £5.00
- 52-Week Low: £2.50
- Year-to-Date Performance: -10%
Future Prospects
Analyst predictions for Achilles Therapeutics indicate:
- Projected Revenue for FY 2023: £8 million
- Expected Pipeline Developments: 3 upcoming clinical trials
- Analyst Consensus Rating: Buy
Achilles Therapeutics plc (ACHL) Mission Statement
Core Mission
Achilles Therapeutics plc aims to revolutionize the treatment of cancer through the development of personalized T-cell therapies. The company is dedicated to harnessing the power of the immune system to create innovative treatments based on tumor-specific neoantigens.
Strategic Objectives
- Develop highly targeted immunotherapies that enhance patient outcomes.
- Focus on the use of next-generation sequencing technologies to identify personalized neoantigens.
- Advance clinical trials to validate the efficacy and safety of new therapies.
Market Focus
The primary clinical focus includes:
- Non-small cell lung cancer (NSCLC)
- Melanoma
- Other solid tumors
Financial Overview
As of the end of Q3 2023, Achilles Therapeutics reported the following financial data:
| Financial Metric | Q3 2023 Amount |
|---|---|
| Total Revenue | £2.2 million |
| R&D Expenses | £12.5 million |
| Net Loss | £10.3 million |
| Cash and Cash Equivalents | £35.7 million |
Partnerships and Collaborations
To further its mission, Achilles Therapeutics has established key partnerships:
- Bristol Myers Squibb: Collaboration on T-cell therapy development.
- UCL (University College London): Joint research initiatives on neoantigen targeting.
- UCL Cancer Institute: Access to advanced cancer research and clinical trials.
Clinical Trials and Pipeline
As of October 2023, Achilles Therapeutics is conducting multiple clinical trials:
| Trial Phase | Indication | Trial Status |
|---|---|---|
| Phase 1 | Non-Small Cell Lung Cancer | Recruiting |
| Phase 2 | Melanoma | Active |
| Phase 1/2 | Additional Solid Tumors | Completed |
Innovative Approach
Achilles Therapeutics employs advanced technologies:
- Neoantigen identification: Utilizing bioinformatics tools to analyze tumor genomics.
- T-cell engineering: Modifying T-cells to enhance their targeting capabilities.
- Adaptive trials: Implementing flexible trial designs to incorporate real-time data and optimize outcomes.
Conclusion of Mission Statement Elements
Achilles Therapeutics plc remains committed to its mission of transforming cancer treatment through innovative personalized therapies, focusing on extensive research and collaboration in the biopharmaceutical landscape.
How Achilles Therapeutics plc (ACHL) Works
Overview of Achilles Therapeutics plc
Achilles Therapeutics plc (ACHL) is a biotechnology company focused on developing personalized cancer immunotherapies. It specializes in utilizing T cell therapy to target neoantigens present in cancer cells. The company’s approach is rooted in proprietary technology designed to identify and exploit specific mutations within individual tumors.
Business Model
Achilles Therapeutics employs a model based on research and development, with a focus on clinical trials to validate its therapies. Its pipeline includes multiple candidates at various stages, notably:
- ACH-101: Currently in Phase 1 clinical trials
- ACH-201: Expected to enter Phase 2 trials in Q2 2024
- ACH-301: Preclinical stage
Financial Performance
In 2022, Achilles Therapeutics reported total revenues of approximately £1.8 million, primarily through grants and collaborations. The company had a net loss of £30.5 million for the same year.
| Year | Total Revenue (£) | Net Loss (£) | Cash Reserves (£) |
|---|---|---|---|
| 2020 | £0.5 million | £15.7 million | £55 million |
| 2021 | £1.2 million | £20.4 million | £45 million |
| 2022 | £1.8 million | £30.5 million | £25 million |
Market Position
As of September 2023, Achilles Therapeutics has a market capitalization of approximately £150 million. The stock price has experienced fluctuations, with a 52-week range between £1.20 and £2.50.
Clinical Trials and Research
Achilles Therapeutics currently has several ongoing clinical trials aimed at evaluating the safety and efficacy of its T cell therapies. The company is actively collaborating with leading cancer research institutions.
- Completed Phase 1 for ACH-101 with positive results reported in Q4 2022
- Initiated Phase 1b trials in Q1 2023 for combination therapies
Investor Relations
Achilles Therapeutics has been proactive in engaging with its investors and stakeholders. Regular updates regarding clinical progress and financial performance are provided during quarterly earnings calls. The most recent earnings call was held on August 15, 2023.
Future Outlook
Analyst projections for Achilles Therapeutics indicate significant potential growth, particularly if the ongoing trials yield successful outcomes. The company is also exploring partnerships to enhance its therapeutic development capabilities.
| Analyst Firm | Recommendation | Target Price (£) |
|---|---|---|
| Goldman Sachs | Buy | £3.00 |
| Jefferies | Hold | £2.00 |
| Bank of America | Buy | £3.50 |
How Achilles Therapeutics plc (ACHL) Makes Money
Revenue Streams
Achilles Therapeutics plc primarily generates revenue through three main avenues: collaborative agreements, grants, and potential future product sales.
Collaborative Agreements
Achilles engages in strategic partnerships with pharmaceutical companies and research institutions. These collaborations often involve upfront payments, milestone payments, and royalties on future sales. For instance, the company entered a collaboration with a major pharmaceutical partner that included an upfront payment of approximately £5 million in 2021.
Grants and Funding
The company actively seeks funding from governmental and private entities that support innovative cancer treatments. In 2023, Achilles Therapeutics secured a grant worth £2 million from the UK government to advance its research on personalized cancer therapies.
Research and Development Expenses
Investment in research and development is critical for Achilles Therapeutics. In 2022, the company reported R&D expenses of £10 million, reflecting its commitment to developing its lead product candidates.
Market Potential and Product Pipeline
Achilles focuses on developing therapies based on T-cell receptor-engineered T-cell therapy (TCR-T). Their lead product candidates are aimed at treating various types of cancer, specifically focused on unmet medical needs. The total addressable market for TCR-T therapies is estimated to reach £30 billion by 2030.
Financial Performance
| Year | Revenue (£ million) | R&D Expenses (£ million) | Net Loss (£ million) |
|---|---|---|---|
| 2021 | 5.0 | 8.0 | 15.0 |
| 2022 | 0.0 | 10.0 | 20.0 |
| 2023 | 2.0 | 12.0 | 25.0 |
Future Prospects
Achilles Therapeutics is in various phases of clinical trials for its product candidates. The successful commercialization of these products is expected to significantly enhance revenue. Analysts project that the company could achieve revenues exceeding £50 million annually by 2025 if clinical trials are successful.
Licensing Agreements
In addition to collaborative agreements, Achilles may explore licensing opportunities for its technologies. Licensing agreements can provide significant royalty income. For example, a successful licensing agreement could yield up to 10% royalties on net sales of licensed products.
Risks and Challenges
- Regulatory hurdles could delay product approvals.
- Dependence on successful clinical trial outcomes.
- Market competition from established pharmaceutical companies.
Summary of Financial Position
| Metric | Amount (£ million) |
|---|---|
| Cash and Cash Equivalents (2023) | 30.0 |
| Total Assets (2023) | 50.0 |
| Total Liabilities (2023) | 25.0 |
| Equity (2023) | 25.0 |
Achilles Therapeutics plc (ACHL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support